As of 10:52am ET
| -0.67 / -1.54%|
The 15 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 49.59, with a high estimate of 59.59 and a low estimate of 40.17. The median estimate represents a +15.71% increase from the last price of 42.86.
The current consensus among 15 polled investment analysts is to Buy stock in Novozymes A/S. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.